LUNG ALERT: Combination treatment may help patients with COPD, but does not improve mortality

Ampikaipakan, Sundari
July 2007
Thorax;Jul2007, Vol. 62 Issue 7, p587
Academic Journal
The article reports on the research findings on combination treatment of patients with chronic obstructive pulmonary disease (COPD). It is stated that although the salmeterol-fluticasone combination failed to demonstrate an improvement in mortality according to the predefined statistical criteria, it did show significant improvement in exacerbation rates, health status and lung function.


Related Articles

  • Combination therapy boosts COPD survival.  // Pulse;Nov2014, p19 

    The article reports on the study published in the "Journal of the American Medical Association" which found that the combination of an inhaled steroid and a long-acting Beta-agonist (LABA) reduces mortality and hospital admissions in patients with chronic obstructive pulmonary disease.

  • Is there a rational for combining long-acting antimuscarinics and β2-agonists? Calzetta, Luigino; Capuano, Annalisa; Rinaldi, Barbara; Matera, Maria G. // Hot Topics in Respiratory Medicine;2014, Vol. 9 Issue 26, p7 

    Asthma and COPD are airway diseases both affected by as of yet not well-elucidated genetic and environmental interactions. Chronic inflammation underlies both diseases. Both conditions involve the small airways, causing a slightly larger decrease in airway function and both cause airway...

  • Optimizing bronchodilatation in COPD: double bronchodilator therapy. Beeh, Kai M.; Beier, Jutta // Hot Topics in Respiratory Medicine;2014, Vol. 9 Issue 26, p13 

    Bronchodilators are the cornerstone of symptomatic treatment for COPD. They are recommended on a regular basis to prevent or reduce symptoms and exacerbations, with a preference for long-acting over short-acting drugs. There are two classes of bronchodilators with distinct modes of action,...

  • Role of bronchodilators in new treatment guidelines. Rubio, Myriam Calle; Guerassimova, Ina; Rodríguez Hermosa, Juan L. // Hot Topics in Respiratory Medicine;2014, Vol. 9 Issue 26, p19 

    In current international clinical guidelines, the bronchodilators still remain the mainstay of COPD therapeutic measures as they have been demonstrated to achieve symptom control, better exercise tolerance and quality of life, improved pulmonary function and prevention of exacerbations. The...

  • Recent advances in pre-clinical mouse models of COPD. VLAHOS, Ross; BOZINOVSKI, Steven // Clinical Science;Feb2014, Vol. 126 Issue 4, p253 

    COPD (chronic obstructive pulmonary disease) is a major incurable global health burden and will become the third largest cause of death in the world by 2020. It is currently believed that an exaggerated inflammatory response to inhaled irritants, in particular cigarette smoke, causes progressive...

  • KRONÄ°K OBSTRÃœKTÄ°F AKCÄ°ÄžER HASTALIÄžI TEDAVÄ°SÄ°. Koçyiğit, Emine // Nobel Medicus Journal;Jan-Apr2007, Vol. 3 Issue 1, p4 

    Chronic Obstructive Pulmonary Disease (COPD) is one of the most common disease in the world which increases in number every year and also makes harmful effects on economy. For this reason National Hearth Lung blood institute (NHLBI) ana World Health Organisation (WHO) established a collaboration...

  • Chronic obstructive pulmonary disease (COPD) treatment in the elderly. Grembiale, R. D.; Naty, S.; Ursini, F. // BMC Geriatrics;2010, Vol. 10, pL83 

    The article discuses various aspects related to the treatment of elderly people suffering from Chronic obstructive pulmonary disease (COPD). As stated, COPD is a very common disease among elderly and is an important cause of morbidity and mortality. The treatment of elderly patients with COPD...

  • Therapy for Chronic Obstructive Pulmonary Disease in the 21st Century. Donnelly, Louise E.; Rogers, Duncan F. // Drugs;2003, Vol. 63 Issue 19, p1973 

    Chronic obstructive pulmonary disease (COPD) is a common, smoking-related, severe respiratory condition characterized by progressive, irreversible airflow limitation. Current treatment of COPD is symptomatic, with no drugs capable of halting the relentless progression of airflow obstruction....

  • Theravance, GSK Testing COPD Combo Treatment.  // Bioworld Week;11/2/2009, Vol. 17 Issue 44, p4 

    The article reports on the start of the first in a series of Phase III studies of next-generation combination treatment for chronic obstructive pulmonary disorder (COPD) of Theravance Inc. and GlaxoSmithKline PLC. The studies will include over 6,000 patients with COPD and will evaluate the rate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics